N. Anthony Coles - Dec 28, 2022 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
Director
Signature
By: Richard Gluckselig as attorney-in-fact For: N. Anthony Coles
Stock symbol
REGN
Transactions as of
Dec 28, 2022
Transactions value $
-$1,565,412
Form type
4
Date filed
12/30/2022, 03:10 PM
Previous filing
Dec 13, 2022
Next filing
Jan 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $802K +2.15K +196.25% $374.12 3.24K Dec 28, 2022 Direct F1
transaction REGN Common Stock Options Exercise $1.74M +3.61K +111.58% $482.68 6.85K Dec 28, 2022 Direct F1
transaction REGN Common Stock Sale -$128K -181 -2.64% $707.87 6.67K Dec 28, 2022 Direct F1
transaction REGN Common Stock Sale -$710 -1 -0.01% $709.92 6.67K Dec 28, 2022 Direct F1
transaction REGN Common Stock Sale -$483K -679 -10.18% $710.63 5.99K Dec 28, 2022 Direct F1, F2
transaction REGN Common Stock Sale -$71.2K -100 -1.67% $711.95 5.89K Dec 28, 2022 Direct F1
transaction REGN Common Stock Sale -$855K -1.2K -20.34% $713.66 4.69K Dec 28, 2022 Direct F1, F3
transaction REGN Common Stock Sale -$730K -1.02K -21.78% $714.61 3.67K Dec 28, 2022 Direct F1, F4
transaction REGN Common Stock Sale -$1.62M -2.27K -61.74% $715.48 1.4K Dec 28, 2022 Direct F1, F5
transaction REGN Common Stock Sale -$223K -311 -22.15% $716.08 1.09K Dec 28, 2022 Direct F1, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -2.15K -100% $0.00* 0 Dec 28, 2022 Common Stock 2.15K $374.12 Direct F1, F7
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -3.61K -100% $0.00* 0 Dec 28, 2022 Common Stock 3.61K $482.68 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2 Represents volume-weighted average price of sales of 679 shares of Company stock on December 28, 2022 at prices ranging from $710.48 to $710.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price.
F3 Represents volume-weighted average price of sales of 1,198 shares of Company stock on December 28, 2022 at prices ranging from $713.17 to $713.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price.
F4 Represents volume-weighted average price of sales of 1,022 shares of Company stock on December 28, 2022 at prices ranging from $714.00 to $714.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price.
F5 Represents volume-weighted average price of sales of 2,266 shares of Company stock on December 28, 2022 at prices ranging from $715.04 to $715.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price.
F6 Represents volume-weighted average price of sales of 311 shares of Company stock on December 28, 2022 at prices ranging from $716.02 to $716.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 28, 2022 at each separate price.
F7 On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.